Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology

Hassan El Hajj1, Julie C Savage1, Kanchan Bisht1

  • 1Axe neurosciences, Centre de recherche du CHU de Québec-Université Laval, 2705, boulevard Laurier, T2-50, Quebec, QC, G1V 4G2, Canada.

Abstract

Insights

Alzheimer's disease (AD) alters microglia, the brain's immune cells, causing them to become larger, stressed, and less effective at clearing amyloid beta plaques. These changes are observed in both mouse models and human AD brains.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Alzheimer's disease (AD) is a common neurodegenerative disorder.
  • AD is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles.
  • Microglia, the brain's immune cells, become reactive to Aβ, potentially impairing cognitive function.

Purpose of the Study:

  • To investigate microglial structural and functional heterogeneity in Alzheimer's disease.
  • To compare microglia in AD model mice with those in healthy controls.
  • To examine microglial changes in relation to amyloid pathology and neuronal health.

Main Methods:

  • Correlative light, transmission, and scanning electron microscopy were employed.
  • Microglia were analyzed in the hippocampus of APP-PS1Δe9 mice and wild-type littermates.
  • Human post-mortem hippocampal samples from AD patients were also examined.

Main Results:

  • Microglial cell bodies were larger and showed signs of stress in AD model mice, particularly near plaques.
  • Microglia in AD models were less phagocytic but contained more fibrillar material and inclusions.
  • Microglial processes in healthy brain regions of AD mice more frequently associated with synapses than those near plaques.
  • Similar microglial changes were observed in human AD brain samples.

Conclusions:

  • Distinct microglial ultrastructural transformations occur in association with amyloid pathology.
  • These microglial changes are conserved between AD mouse models and human patients.
  • Understanding these microglial alterations is crucial for developing AD therapies.